Compare Roblox Corp (RBLX) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roblox Corp vs Travere Therapeutics Inc. Common Stock — how do they compare? Roblox Corp trades at $46.7 (market cap $35.37B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Roblox Corp is far larger — about 7.2× Travere Therapeutics Inc. Common Stock's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Roblox Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Roblox Corp for 94 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| RBLX | TVTX | |
|---|---|---|
Market Cap | $35.37B | $4.88B |
Volume | 6,569,814 | 1,668,577 |
Sector | Technology | Health |
52-Week High | $138.56 | $67.52 |
52-Week Low | $35.54 | $26.79 |
Typical Hold Time | 94 Days | 0 Days |
Enterprise Value | $34.19B | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Roblox (RBLX) trades at $49.53, down 0.12% on the day, with the stock showing resilience after recent volatility. The company continues to demonstrate strong revenue growth, reaching $4.89 billion in 2025, though profitability remains elusive with a net income margin of -17.61%. Technical indicators show a bullish trend with the current price near key resistance at $50, while analyst sentiment is mixed with a $52 consensus target. Recent news highlights both optimism around AI integration and concerns about bookings growth sustainability.
Roblox presents a growth story with expanding revenue and improving cash flow, but faces significant profitability challenges. The stock's upside potential hinges on continued user growth and margin improvement, while risks include intense competition and execution challenges in monetization. With mixed analyst ratings and high valuation multiples, investors should weigh the company's long-term platform potential against persistent losses.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Roblox Corp
Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
